Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Metformin Versus Acarbose Treatment in Infertile Overweight Women With Polycystic Ovary Syndrome (PCOS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Royan Institute
ClinicalTrials.gov Identifier:
NCT01279512
First received: January 17, 2011
Last updated: January 5, 2012
Last verified: August 2006

January 17, 2011
January 5, 2012
December 2006
December 2008   (final data collection date for primary outcome measure)
Weight reduction (BMI improvement) [ Time Frame: After 3 months of Metformin or Acarbose ] [ Designated as safety issue: Yes ]
compare the effect of Metformin and Acarbose to weight reduction
Same as current
Complete list of historical versions of study NCT01279512 on ClinicalTrials.gov Archive Site
  • Fasting blood sugar (FBS) [ Time Frame: two hours post prandial blood sugar ] [ Designated as safety issue: No ]
    Compare the effect of Metformin and acarbose to fasting blood sugar reduction
  • FSH [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    compare the effect of Metformin and Acarbose to decrease the level of FSH
  • LH [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    compare the effect of Metformin and Acarbose to decrease the level of LH
  • Estradiol [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    compare the effect of Metformin and Acarbose to decrease the Esteradiol level
  • Prolactin [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    compare the effect of Metformin and Acarbose to decrease the Prolactin level
  • Total testosterone [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    compare the the effect of Metformin and Acarbose to decrease Total testosterone level
  • Total cholesterol [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    comparethe the effect of Metformin and Acarbose to decrease total cholesterol level
  • triglyceride [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    comparethe the effect of Metformin and Acarbose to decrease the triglyceride level
  • High density Lipoprotein [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    compare the the effect of Metformin and Acarbose to decrease high density lipoprotein
  • Low density lipoprotein [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    compare the the effect of Metformin and Acarbose to decrease Low Density Lipoprotein
Same as current
Not Provided
Not Provided
 
Metformin Versus Acarbose Treatment in Infertile Overweight Women With Polycystic Ovary Syndrome (PCOS)
Metformin vs. Acarbose Treatment in Infertile Overweight Women With PCOS: A Prospective Randomized Clinical Trial

This study is a prospective randomized clinical trial to compare the endocrine and metabolic effects of two anti diabetic drugs (metformin vs. acarbose) in infertile overweight women with PCOS

This study is a prospective randomized clinical trial to compare the endocrine and metabolic effects of two anti diabetic drugs (metformin vs. acarbose) in infertile overweight women with PCOS.

Polycystic ovary syndrome (PCOS) is characterized by menstrual irregularity, hyperandrogenism, chronic anovulation and enlarged ovaries with more than twelve peripherally located follicles less than 10 mm in diameter. Hyperinsulinemia is one of the diagnostic features of PCOS and patients with PCOS are found to have resistance to either endogenous or exogenous insulin. Different insulin sensitizing drugs used for improvement of hyperinsulinemia in PCOS subjects. Metformin (N dimethyl-biguanide) is an anti diabetic drug that increases glucose utilization in insulin sensitive tissues. Acarbose is an alfa-Glycosidase inhibitor acts by slowing the absorption of carbohydrates from the intestine, prevents Glucosidase activity in the brush-border of the intestinal mucosa, decreasing disaccharide digestion, reducing enteric monosaccharide absorption, so minimizing the postprandial rise of blood glucose concentration. The aim of present study is to compare the endocrine and metabolic effects of these two antidiabetic drugs (metformin vs. acarbose) in infertile overweight women with PCOS.

The study population comprises all infertile patients with diagnosis of polycystic ovarian syndrome who were overweight (BMI>25Kg/m2). The PCO subjects will be recognized based on the Rotterdam criteria inclusive 1) irregular menstruation, 2) clinical and /or biochemical signs of hyperandrogenism, 3) polycystic ovaries (presence of 12 or more follicles in each ovary measuring 2-9 mm in diameter, and /or increased ovarian volume greater than 10 ml). Diagnosis of PCOS was confirmed by the presence two of three criteria beside the infertility.

In this study all eligible patients will be randomly allocated into two study groups by a computerized randomization method:

Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks). Metformin group will be received metformin. The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.

Data collection will be performed by using questionnaire to be filled as per the available records and laboratory results. This study will be accomplished in Royan Institute on 50 PCO patients (25 patients in each group) and a continuous sampling method will be applied. Data analysis will be done through descriptive and perceptive statistical methods by using SPSS software version 15 for windows.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
PCO
  • Drug: Metformin
    The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.
    Other Name: Metformin description
  • Drug: Acarbose
    Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks).
    Other Name: Acarbose description
  • Experimental: Metformin reciepiants
    Infertile overweight women with PCO who received Metformin
    Intervention: Drug: Metformin
  • Experimental: Acarbose reciepiants
    Infertile overweight women with PCO who received Acarbose
    Intervention: Drug: Acarbose
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
December 2008
December 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Poly Cystic Ovarian Syndrome patients
  • Age < 40 years
  • BMI > 25 kg/m2

Exclusion Criteria:

  • Smoking
  • Overt diabetes mellitus, hyperprolactinemia, diseases that would disturb clinical and hormonal responses (adrenal disease or tumors, ovarian tumors, thyroid disease)
  • The use of hormonal medications or drugs that might interfere with carbohydrate metabolism over the last 6 months.
Female
18 Years to 40 Years
No
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
 
NCT01279512
Royan-Emb-011
Yes
Royan Institute
Royan Institute
Not Provided
Study Chair: Ashraf Moini, MD Scientific board
Study Director: Elham Amirchaghmaghi, MD Invetigator
Principal Investigator: Zhila Ahmadi, BS.c Investigator
Principal Investigator: Bita Eslami, MPH Investigator
Principal Investigator: Ali asghar Akhlaghi, BS.c Investigator
Principal Investigator: Reza salmanyazdi, MLD Investigator
Royan Institute
August 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP